Research Pharmacy SOP: Structure, Sections & Worked Example

A research pharmacy (Investigational Drug Service, IDS) does not operate on judgment call alone — it operates against a written Standard Operating Procedure (SOP) that spells out, step by step, how investigational product moves from receipt to final disposition. CASRAI’s research pharmacy dictionary entry covers what the function is and the regulatory obligations behind it. This guide answers a more practical, frequently-searched question: what does an actual research-pharmacy SOP contain, section by section, and what does representative SOP language look like.

Why the SOP exists (the regulatory basis)

ICH E6(R2) Good Clinical Practice Section 5.14 requires the sponsor to maintain systems and written procedures for the shipment, receipt, storage, dispensing, retrieval of unused product, and return or destruction of investigational product. Section 4.6 assigns the investigator/institution responsibility for accountability at the site and explicitly permits that responsibility to be delegated to a pharmacist or another qualified individual under the investigator’s supervision. A site’s research-pharmacy SOP is the document that discharges that delegated obligation in writing — it is what a monitor reviews at a site visit and what a regulatory inspector expects to see during a Bioresearch Monitoring (BIMO)-type inspection. In the US, FDA regulation 21 CFR 312.62 separately requires the investigator to maintain adequate records of drug disposition (dates, quantities, and use by subjects) and to return or otherwise dispose of unused supplies at the end of an investigation — obligations the SOP’s accountability and destruction sections exist to satisfy. See CASRAI’s ICH E6(R2) and Good Documentation Practices in Clinical Trials guides for the broader documentation framework this sits inside.

The standard SOP structure

Published IDS/research-pharmacy SOPs converge on a similar document skeleton, whether the section numbers or exact headings vary slightly by institution:

1. Purpose and scope — what the SOP governs (typically: all investigational drug products handled by the site’s research pharmacy) and what it explicitly excludes (e.g., commercially available comparator drugs sourced through routine hospital pharmacy channels, which may be covered by a separate SOP).
2. Responsibilities — who does what: the Principal Investigator (overall accountability), the research/IDS pharmacist (day-to-day receipt, storage, dispensing, accountability), and, in blinded trials, a designated unblinded pharmacist whose randomization-code access is walled off from staff assessing subject outcomes.
3. Definitions and abbreviations — IP/IMP, IDS, accountability log, destruction log, excursion, delegation of authority log, and any trial-specific terms drawn from the protocol’s pharmacy manual.
4. Procedure — the operational core, almost always broken into the same sub-sections described below.
5. Records and forms referenced — the specific logs and forms the procedure section points to.
6. References — the regulations, guidelines, and institutional policies the SOP is written to satisfy (ICH E6, applicable national regulation, ASHP/HOPA guidance, the trial’s own pharmacy manual).
7. Revision history — version number, date, summary of change, and approval signatures — itself an auditable record, since a monitor or inspector may ask which SOP version was in effect on a given date.

Inside the procedure section: what each subsection covers

The procedure section is where most of the operational detail — and most of what an inspector actually checks — lives:

• 4.1 Receipt and verification — confirming a shipment against the sponsor’s packing list/manifest, checking shipment temperature-monitoring device data on arrival, documenting condition and quantity discrepancies, and logging receipt in the accountability system before product is placed into storage.
• 4.2 Storage and temperature monitoring — storage location, access controls, and continuous temperature monitoring (refrigerated, frozen, or controlled room temperature as the protocol/pharmacy manual specifies), including the defined excursion procedure: what temperature range triggers an excursion report, who is notified, and how the sponsor’s medical monitor or IP quality team is consulted on product disposition before it is dispensed.
• 4.3 Inventory and drug accountability — the perpetual accountability log recording every unit from receipt through final disposition, reconciled periodically against dispensing records and subject visit schedules, and made available for CRA monitoring visits and regulatory inspection on request.
• 4.4 Randomization and blinding support — how the unblinded pharmacist accesses the randomization code (interactive response technology/IRT system credentials, sealed code-break envelopes, or equivalent), and the firewall preventing that information from reaching blinded study team members.
• 4.5 Dispensing — verifying an active IRB/ethics-committee approval and current informed consent are on file, confirming subject eligibility and randomization assignment, and dispensing only the protocol-specified dose/formulation against a pharmacy order, not an open prescription.
• 4.6 Compounding and preparation — where applicable (common in oncology and infusion trials), reconstitution or dilution performed under the same GCP standards, and, in the US, USP compounding-standard practices that apply to any sterile or non-sterile preparation.
• 4.7 Subject return and reconciliation — counting and documenting product a subject returns (used, unused, or partially used), reconciling it against what was dispensed, and flagging discrepancies for investigator follow-up (a compliance/adherence signal as well as an accountability one).
• 4.8 Return to sponsor or on-site destruction — documenting final disposition of unused, expired, or discontinued product: either shipment back to the sponsor or its designated destruction vendor, or on-site destruction under a sponsor-authorized method, witnessed and co-signed per the SOP’s requirement, with the destruction log itself becoming an essential document retained with the site’s other trial records.

Illustrative SOP language: the dispensing subsection

To make the structure above concrete, here is representative language for a single subsection — illustrative only, not copied from any real institution’s document:

What monitors and inspectors typically focus on

Across published GCP-inspection guidance and monitoring practice, the accountability and destruction sections of a research-pharmacy SOP tend to draw the closest scrutiny, because they are where a paper trail either closes cleanly or doesn’t: accountability logs that don’t reconcile against dispensing and subject visit records, temperature excursions without a documented disposition decision, destruction records missing a required witness signature, or dispensing that predates a current IRB/consent approval on file. An SOP that specifies exactly who signs what, when, and against which log is what lets a site demonstrate — quickly, during a monitoring visit or inspection — that these steps actually happened in the order the SOP requires.

Frequently asked questions

Who writes and approves a research pharmacy SOP?

Typically the institution’s IDS/research pharmacy leadership drafts it, in coordination with the institution’s clinical trials office or research compliance office, with formal approval and version control managed through the site’s quality-assurance or pharmacy-department SOP governance process — not by an individual trial’s sponsor, though the SOP must be broad enough to accommodate the specific requirements each trial’s protocol and pharmacy manual impose.

Does every trial need its own SOP, or does one site-level SOP cover everything?

Most sites operate one overarching research-pharmacy SOP covering the general process (receipt, storage, accountability, dispensing, destruction), supplemented by trial-specific instructions from that protocol’s sponsor-provided pharmacy manual, which addresses drug-specific handling requirements (e.g., a particular temperature range or a specific unblinding procedure) the general SOP does not, and cannot, anticipate in advance.

How long are research pharmacy accountability records retained?

In the US, 21 CFR 312.62(c) requires investigator records — which include drug-disposition and accountability records — to be retained for two years following marketing-application approval for the studied indication, or, if no application is filed or approved, until two years after the investigation is discontinued and FDA is notified. Institutional policy and sponsor contract terms may require longer retention; the SOP should state the site’s actual applicable retention period rather than leave it to individual interpretation.

What’s the difference between the drug accountability log and the destruction log?

The accountability log is the continuous, cradle-to-grave record of every unit from receipt through final disposition. The destruction log is the specific record generated at the point of on-site destruction — documenting method, quantity, date, and witness signatures — that closes out the accountability log’s entry for that product once destruction is confirmed.

Related CASRAI resources

• Research Pharmacy (Investigational Drug Service, IDS) — the conceptual overview of the function and its regulatory basis.
• Investigational Medicinal Product (IMP) — the regulatory definition of the product the SOP governs.
• Trial Master File (TMF) — where accountability and destruction records fit within the site’s essential documents.
• Good Documentation Practices (GDP) in Clinical Trials — the broader documentation-quality principles an SOP’s records must meet.
• Clinical Trial Monitoring — how CRAs review pharmacy accountability records during monitoring visits.
• Decentralized Clinical Trials — how direct-to-participant shipment models change (without eliminating) the accountability obligations described here.
• The Cost of Running a Clinical Trial — where research-pharmacy staffing and dispensing costs fit in overall trial budgeting.